Mangoceuticals (MGRX) Cash & Equivalents (2023 - 2026)

Mangoceuticals has disclosed Cash & Equivalents across 4 years of filings, most recently posting $228688.0 for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 126.38% year-over-year to $228688.0; the TTM figure through Jun 2026 stood at $228688.0 (up 126.38% YoY), while the FY2025 annual figure was $1.5 million, up 2434.12% from the prior year.
• Cash & Equivalents came in at $228688.0 for Q2 2026 at Mangoceuticals, up from $174562.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $3.8 million in Q1 2023 to a low of $15305.0 in Q1 2024.
• Average Cash & Equivalents over 4 years is $850068.6, with a median of $354984.5 recorded in 2025.
• Year-over-year, Cash & Equivalents tumbled 99.6% in 2024 and soared 2434.12% in 2025.
• Over 4 years, Cash & Equivalents stood at $739006.0 in 2023, then slumped by 92.06% to $58653.0 in 2024, then soared by 2434.12% to $1.5 million in 2025, then plunged by 84.61% to $228688.0 in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $228688.0 in Q2 2026, $174562.0 in Q1 2026, and $1.5 million in Q4 2025.